Timothy L. Moore is VP at Kite Pharma, Inc. (KITE). They have made 6 open-market trades across 3 companies since 2017, most recently 2026-02-24.
CIK 0001669207
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $32K since 2020, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALLO | SELL | 2025-02-03 | 2025-02-05 | $1.71 | $25K | +72.1% | +32.1% | -22.4% |
| CERS | BUY | 2020-02-11 | 2020-02-13 | $4.75 | $17K | +8.7% | -24.6% | +8.5% |
| CERS | BUY | 2020-01-29 | 2020-02-03 | $4.15 | $15K | +10.0% | +22.6% | +18.7% |
| KITE | SELL | 2017-08-03 | 2017-08-04 | $110.06 | $1.3M | +13.2% | +57.3% | N/A |
| KITE | SELL | 2017-08-01 | 2017-08-03 | $107.67 | $2.5M | +14.6% | +60.9% | N/A |
| KITE | SELL | 2017-03-15 | 2017-09-27 | $118.01 | $2.8M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.